NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp(University Hospital of Lausanne), Eric T. Wong(Harvard University Press), Andrew A. Kanner(Tel Aviv Sourasky Medical Center), David Steinberg(Tel Aviv University), Herbert H. Engelhard(University of Illinois Chicago), Volkmar Heidecke, Eilon D. Kirson(Novocure (United States)), Sophie Taillibert(Sorbonne Université), Frank Liebermann(University of Pittsburgh), Vladimír Dbalý(Na Homolce Hospital), Zvi Ram(Tel Aviv Sourasky Medical Center), John L. Villano(University of Illinois Chicago), Nikolai G. Rainov, Uri Weinberg(Novocure (United States)), David Schiff(University of Virginia), Lara J. Kunschner, Jeffrey J. Raizer(Northwestern University), Jérôme Honnorat(Université Claude Bernard Lyon 1), Andrew E. Sloan(University Hospitals of Cleveland), Mark G. Malkin(Medical College of Wisconsin), Joseph Landolfi, Franz Payer(University of Graz), H. Maximilian Mehdorn(Christian-Albrechts-Universität zu Kiel), Robert J. Weil(Cleveland Clinic), Susan C. Pannullo(Cornell University), Manfred Westphal(Universität Hamburg), Martin Smrčka(Masaryk University), Lawrence S. Chin, H. Kostron(Universität Innsbruck), Silvia Höfer(University of Zurich), Jeffrey N. Bruce(Columbia University), Rees Cosgrove(Tufts University), Nina Paleologous(NorthShore University HealthSystem), Yoram Palti(Novocure (United States)), Philip H. Gutin(Memorial Sloan Kettering Cancer Center)
Cited by 842